Babson Diagnostics Welcomes Four New Leaders to Management Team

AUSTIN, Texas–(BUSINESS WIRE)–Babson Diagnostics, a science-first health care technology company, today announced that it continues to grow its management team with the addition of four key leaders. The new team members bring skill sets and experience that will support the commercial launch of its blood testing ecosystem, which reimagines blood testing from collection to sample preparation to analysis, to better meet the needs of the modern clinician and consumer.

Babson’s new additions include:

Dominic Weilbaecher, Vice President, Payer Relations: Weilbaecher will be responsible for leading payer engagement and market access strategy. He brings more than 20 years of experience in reimbursement, revenue cycle management, and contracting strategies that enhance collaboration and financial success. He was regional sales director of health plans at Quest Diagnostics and has led market access for Agendia, Oncocyte, BillionToOne, and Pathnostics. In addition, Weilbaecher has consulted for laboratories in reimbursement, medical policy inclusion, and contracting.

Dasha McCarthy, Vice President, Clinician Relations: McCarthy will lead the engagement and partnership strategy with health care professionals to build trusted and long-lasting relationships. Most recently, she was vice president of regional sales for the west at Pathnostics, a diagnostics solutions company specializing in infectious disease and anatomic pathology testing. She has also led sales operations for Pathology Inc., the largest privately-owned women’s health lab on the West Coast.

Roland Schneider, Vice President, Manufacturing: Schneider will lead the design, development, and deployment of the company’s manufacturing operations, focused on electromechanical and mechatronics devices. He will work closely with the research and development teams to transfer design and scale production to support commercial launch. He has an extensive background in manufacturing operations management in the medical industry, including diagnostics, surgical tools, and point-of-care equipment.

David “Dutch” Vandersand, Vice President, Supply Chain: Vandersand will be responsible for leading procurement and supply chain strategy. He brings more than 20 years of medical device experience in procurement, planning, operations, and customer service. Vandersand has deep expertise in resilient and scalable supply chains, new-product introduction, collaborative supplier management, and effective technology deployment. Most recently he was vice president of manufacturing and operations at Lima USA, a global orthopedics company.

“With the addition of Dominic, Dasha, Roland, and David to the Babson family, we continue to add experienced, passionate leaders to our team,” said David Stein, chief executive officer. “All four of these individuals will play an integral role in fulfilling Babson’s mission of making blood testing more accessible and customer-centered.”

Babson is building a best-in-class team committed to empowering people to take charge of their health through medically accurate, convenient, and less-invasive diagnostic testing at retail pharmacies and new care settings. The company is conducting extensive clinical studies of its state-of-the-art capillary collection device, developed in partnership with Becton, Dickinson and Company (BD), and its service platform in preparation for commercial launch.

About Babson Diagnostics

Babson Diagnostics is a science-first health care technology company reimagining the entire diagnostic blood testing experience. Babson’s mission is to make routine blood testing less invasive, more convenient, and affordable, empowering people to take charge of their health.

Babson will bring medically accurate blood testing to the retail pharmacy by using patented technologies and a first-of-its-kind ecosystem that requires only one-tenth the sample volume of traditional venipuncture methods without sacrificing quality, accuracy, or menu breadth.

The company has received key patents in the United States, European Union, and China related to its unique end-to-end technological ecosystem and the ability to maximize the clinical utility of microsamples of blood collected from a fingertip. In addition, Babson has fully validated a broad set of miniaturized assays that are ready for commercial use in its CLIA-certified laboratory.

Babson, based in Austin, Texas, was founded by individuals with deep experience in healthcare, diagnostics, engineering, and laboratory technologies. The company is named in honor of Art Babson, whose legacy of scientific innovation and excellence is the foundation on which the company is built.

For more information, please visit www.BabsonDX.com.

Find more, like the above, right here on Cryptopolytech.com by following our extensive quiclick links appearing on images or within categories [NEWSer CHEWSer].

Source Information (if available)

It appears the above article may have originally appeared on www.businesswire.com and has been shared elsewhere on the internet, repeatedly. News articles have become eerily similar to manufacturer descriptions.

We will happily entertain any content removal requests, simply reach out to us. In the interim, please perform due diligence and place any content you deem “privileged” behind a subscription and/or paywall.